Meta-analysis - Eltrombopag

Eltrombopag in Chronic ITP

NCT04102033 ·Status: UNKNOWN ·Phase: PHASE4

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

NCT00902018 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00908037 ·Status: COMPLETED ·Phase: PHASE2

Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

NCT06137105 ·Status: NOT_YET_RECRUITING

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

NCT03830749 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

NCT03771378 ·Status: UNKNOWN ·Phase: PHASE4

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331 ·Status: COMPLETED ·Phase: PHASE3

Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

NCT04917679 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612 ·Status: COMPLETED ·Phase: PHASE2

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

NCT02877212 ·Status: UNKNOWN ·Phase: PHASE3

Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP

NCT05846529 ·Status: UNKNOWN

Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

NCT01439321 ·Status: COMPLETED

Eltrombopag for Inherited Thrombocytopenias

NCT02422394 ·Status: COMPLETED ·Phase: PHASE2

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

NCT02158936 ·Status: TERMINATED ·Phase: PHASE3

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

NCT00359463 ·Status: COMPLETED ·Phase: PHASE1

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00540423 ·Status: COMPLETED ·Phase: PHASE3

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT02201290 ·Status: COMPLETED ·Phase: PHASE3

Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

NCT07059910 ·Status: NOT_YET_RECRUITING

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT01098487 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of Eltrombopag at Escalated Doses

NCT01880047 ·Status: COMPLETED ·Phase: PHASE2

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

NCT03638817 ·Status: COMPLETED ·Phase: PHASE2

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

NCT02281370 ·Status: COMPLETED ·Phase: PHASE1

A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

NCT04214951 ·Status: UNKNOWN

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

NCT04132050 ·Status: COMPLETED ·Phase: PHASE3